Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

BOIRON : Projected timetable of the next publications and events 2023

The projected timetable of the next publications and events for the year 2023 is the following one:

Publications Date of publication (after market closing) Information meetings
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin: https://mailing-ircockpit.eqs.com/crm-mailing/5b71ace0-ea7c-11e8-902f-2c44fd856d8c/65f595ef-da60-4064-99d1-181beba25997/ffa06e1c-1aba-4823-afe3-08daee1c52d3/Table+H1+2022.png
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
The Bastide Group enters the respiratory care devices market in Italy

Caissargues, July 18, 2022

The Bastide Group announces the acquisition of a majority stake in Oxystore, a company based near Milan, Italy. Oxystore specializes in home diagnosis and online sales of

DGAP-News: Gerresheimer AG: Gerresheimer on track to deliver record financial year 2022 after solid second quarter: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=85c048fbb4ee10465aa5d2e506a41595
DGAP-News: Gerresheimer AG: Gerresheimer on track to deliver record financial year 2022 after solid second quarter
DGAP-News: Gerresheimer AG: Gerresheimer on track to deliver record financial year 2022 after solid second quarter
Theranexus publishes its cash position as of 30 june 2022

Lyon, France – 12 July 2022 – 6 pm CEST –  Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating

Maria Soler Nunez appointed as Head, Group Operations: https://mailing-ircockpit.eqs.com/crm-mailing/5b71ace0-ea7c-11e8-902f-2c44fd856d8c/da75bbed-f3bc-4a1d-9875-d27419257884/44372190-575f-48fc-882c-357bfd2721ce/MSN.jpg
Maria Soler Nunez appointed as Head, Group Operations
Maria Soler Nunez appointed as Head, Group Operations
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=4d0c5b6b32708f0543d895c3b29a2277
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations
Quantum Genomics announces the appointment of its new Scientific Advisory Board

Quantum Genomics announces the appointment of its new Scientific Advisory Board

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=a9745ad9af6824f7d988e3dabb8be4ea
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
THERANEXUS PARTICIPATES IN SEVERAL LEADING SCIENTIFIC CONFERENCES AND BUSINESS CONVENTIONS

Lyon, France – 9 June 2022– 6 pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=a2e20e899e5ab994754dd16899a8a74c
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=76e2f0335d941bedb39fe6be92218959
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry
BASTIDE : Acceleration in growth in the third quarter, to 6% - Outlook confirmed

Caissargues, May 12, 2022

 

In €k 2020-2021 2021-2022 Change 3rd quarter revenue 111,669 118,446 +6.1% 9-month revenue 333,033 341,491 +2.5%

 

 

Group

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development

QUANTUM GENOMICS : Publication of the Universal Registration Document

Publication of the Universal Registration Document

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal

Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity

Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the

QUANTUM GENOMICS : Update of Shareholding Situation Following April 27, 2022 Capital Raise

Update of Shareholding Situation Following April 27, 2022 Capital Raise

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a

Quantum Genomics announces successful capital raising with a gross sum of approximately EUR 15.6 M EUR

Quantum Genomics announces successful capital raising with a gross sum of approximately €15.6 M€

  • Quantum Genomics has equipped itself with new financial means to pursue the development of
Quantum Genomics Raises a Gross Amount of Approximately EUR 15 M

Quantum Genomics Raises a Gross Amount of Approximately € 15 M

  • Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases

Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating

BOIRON : 2022 first quarter sales

(Unaudited data)

In thousands of euros 2022 2021 Variation at current exchange rates Variation at constant exchange rates France 77,055 51,518 +49.6% +49.6% Europe
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new

QUANTUM GENOMICS : Stéphane Cohen joins Quantum Genomics as Director of Global Operations

Stéphane Cohen joins Quantum Genomics as Director of Global Operations

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new